Clinical implication of serum sIL-2R levels in ovarian cancer.
The levels of serum soluble interleukin-2 receptor (sIL-2R) of 36 patients with ovarian cancer, 34 with benign gynecological tumors and 31 blood donors were measured by ELISA. Compared to those of benign and normal controls, serum levels of sIL-2R in patients with ovarian cancer elevated significantly (P < 0.01). Serum sIL-2R levels were likely related to types, clinical stage or histological grading of ovarian cancer. We were led to conclude that serum sIL-2R level may reflect the status of the immune system and the disease severity in patients with ovarian cancer. Its value as a marker for monitoring treatment and prognosis needs further studies.
Wang
S
S
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical University, Wuhan.
Cai
G
G
Lu
Y
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D002648:Child; D018282:Cystadenocarcinoma, Mucinous / Q000097:blood; D018284:Cystadenocarcinoma, Serous / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood*; D015375:Receptors, Interleukin-2 / Q000097:blood*; D013724:Teratoma / Q000097:blood
D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2